Repligen's Q1 revenue declined by 20% organically, driven by Covid-related business decline and reduced demand in China and protein business. Strong growth and pipelines in the core filtration ...
In the latest quarter, 4 analysts provided ratings for Repligen (NASDAQ:RGEN), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates ...
Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback